Home › Trial NCT04830267
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
- Trial IDNCT04830267
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorChongqing University Cancer Hospital
- Enrollment39
- Start date2021-03-01
- ConditionsNasopharyngeal Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.